Pharma Foods International Overview
- Year Founded
-
1997
- Status
-
Public
- Employees
-
613
- Stock Symbol
-
2929
- Investments
-
7
- Share Price
-
$3.44
- (As of Tuesday Closing)
Pharma Foods International General Information
Description
Pharma Foods International Co Ltd with its subsidiaries involves in the research, development, and manufacturing of functional ingredients, healthfoods, and pharmaceuticals, which are then sold to food and pharmaceuticalmanufacturers, distributors, and other businesses. The group operates in three segments, which include B2B, B2C, and Biomedical business.
Contact Information
Website
www.pharmafoods.co.jpCorporate Office
- 1-49 Goryo-Ohara, Nishikyo-ku
- Kyoto, 615-8245
- Japan
Corporate Office
- 1-49 Goryo-Ohara, Nishikyo-ku
- Kyoto, 615-8245
- Japan
Pharma Foods International Stock Performance
As of 17-Nov-2026, Pharma Foods International’s stock price is $3.44. Its current market cap is $100M with 29M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.44 | $3.51 | $3.20 - $5.18 | $100M | 29M | 234K | $0.44 |
Pharma Foods International Financials Summary
As of 31-Jul-2026, Pharma Foods International has a trailing 12-month revenue of $406M.
|
In Thousands, USD |
TTM 31-Jul-2026 | FY 2026 31-Jul-2026 | FY 2025 31-Jul-2025 | FY 2024 31-Jul-2024 |
|---|---|---|---|---|
| EV | 153,884 | 153,884 | 180,548 | 220,028 |
| Revenue | 405,953 | 405,953 | 438,753 | 412,853 |
| EBITDA | 20,367 | 20,367 | 21,857 | 39,215 |
| Net Income | 12,765 | 12,765 | 2,474 | 21,291 |
| Total Assets | 219,195 | 219,195 | 218,748 | 239,564 |
| Total Debt | 107,185 | 107,185 | 84,628 | 110,641 |
Pharma Foods International Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Pharma Foods International Patents
Pharma Foods International Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-7788776-B1 | Preservative to prevent deterioration of cooked rice | Active | 09-Jun-2025 | ||
| WO-2026094824-A1 | Use of pad inhibitor for treatment or prevention of autoimmune arthritis | Pending | 01-Nov-2024 | ||
| WO-2025254163-A1 | Anti-cadm1 antibody and antigen-binding fragment thereof | Pending | 04-Jun-2024 | ||
| WO-2025254162-A1 | Pharmaceutical composition for use in treatment of cadm1-related diseases and use thereof | Pending | 04-Jun-2024 | ||
| JP-7656375-B1 | Deterioration-suppressed cooked rice and its manufacturing method | Active | 31-May-2024 |
Pharma Foods International Signals
Pharma Foods International Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Pharma Foods International Investments & Acquisitions (7)
Pharma Foods International’s most recent deal was a Merger/Acquisition with Marine Profoods for . The deal was made on 06-Oct-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Marine Profoods | 06-Oct-2026 | Merger/Acquisition | Food Products | ||
| CML (Wholesaler) | 02-Apr-2025 | Corporate | Distributors/Wholesale | ||
| Daicel (Healthcare Mail Order Business) | 20-Sep-2023 | Merger/Acquisition | Food Products | ||
| Eneggo | 29-Jul-2022 | Seed Round | Agricultural Chemicals | ||
| Antegral (Bioscience Business) | 01-Apr-2022 | Merger/Acquisition | Biotechnology |
Pharma Foods International ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.22 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Pharma Foods International Affiliates
Subsidiaries (5)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Onkyo (Home Audio and Video Business Unit) | Osaka, Japan | 2020 | |
| PF Capital | Kyoto, Japan | 2013 | |
| Future Labo | Tokyo, Japan | 2003 | |
| Meiji Yakuhin Kk | Toyama, Japan | 1948 | |
| Pharmafoods Communication | Fukuoka Chuoku, Japan |
Pharma Foods International FAQs
-
When was Pharma Foods International founded?
Pharma Foods International was founded in 1997.
-
Where is Pharma Foods International headquartered?
Pharma Foods International is headquartered in Kyoto, Japan.
-
What is the size of Pharma Foods International?
Pharma Foods International has 613 total employees.
-
What industry is Pharma Foods International in?
Pharma Foods International’s primary industry is Food Products.
-
Is Pharma Foods International a private or public company?
Pharma Foods International is a Public company.
-
What is Pharma Foods International’s stock symbol?
The ticker symbol for Pharma Foods International is 2929.
-
What is the current stock price of Pharma Foods International?
As of 17-Nov-2026 the stock price of Pharma Foods International is $3.44.
-
What is the current market cap of Pharma Foods International?
The current market capitalization of Pharma Foods International is $100M.
-
What is Pharma Foods International’s current revenue?
The trailing twelve month revenue for Pharma Foods International is $406M.
-
What is Pharma Foods International’s annual earnings per share (EPS)?
Pharma Foods International’s EPS for 12 months was $0.44.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process